|
US3773919A
(en)
|
1969-10-23 |
1973-11-20 |
Du Pont |
Polylactide-drug mixtures
|
|
US3941763A
(en)
|
1975-03-28 |
1976-03-02 |
American Home Products Corporation |
PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates
|
|
US4263428A
(en)
|
1978-03-24 |
1981-04-21 |
The Regents Of The University Of California |
Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
|
|
IE52535B1
(en)
|
1981-02-16 |
1987-12-09 |
Ici Plc |
Continuous release pharmaceutical compositions
|
|
DE3374837D1
(en)
|
1982-02-17 |
1988-01-21 |
Ciba Geigy Ag |
Lipids in the aqueous phase
|
|
HUT35524A
(en)
|
1983-08-02 |
1985-07-29 |
Hoechst Ag |
Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
|
|
EP0143949B1
(en)
|
1983-11-01 |
1988-10-12 |
TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION |
Pharmaceutical composition containing urokinase
|
|
US4683202A
(en)
|
1985-03-28 |
1987-07-28 |
Cetus Corporation |
Process for amplifying nucleic acid sequences
|
|
US4965188A
(en)
|
1986-08-22 |
1990-10-23 |
Cetus Corporation |
Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
|
|
US4683195A
(en)
|
1986-01-30 |
1987-07-28 |
Cetus Corporation |
Process for amplifying, detecting, and/or-cloning nucleic acid sequences
|
|
US4800159A
(en)
|
1986-02-07 |
1989-01-24 |
Cetus Corporation |
Process for amplifying, detecting, and/or cloning nucleic acid sequences
|
|
US5453269A
(en)
|
1986-04-14 |
1995-09-26 |
The General Hospital Corporation |
Heterobifunctional antibodies having dual specificity for fibrin and thrombolylic agents and methods of use
|
|
WO1988007089A1
(en)
|
1987-03-18 |
1988-09-22 |
Medical Research Council |
Altered antibodies
|
|
US5559212A
(en)
|
1988-04-06 |
1996-09-24 |
Alfacell Corporation |
Frog embryo and egg-derived tumor cell anti-proliferation protein
|
|
US6780613B1
(en)
|
1988-10-28 |
2004-08-24 |
Genentech, Inc. |
Growth hormone variants
|
|
US5225538A
(en)
|
1989-02-23 |
1993-07-06 |
Genentech, Inc. |
Lymphocyte homing receptor/immunoglobulin fusion proteins
|
|
US5840840A
(en)
|
1990-04-17 |
1998-11-24 |
The United States Of America As Represented By The Department Of Health And Human Services |
Selective RNase cytotoxic reagents
|
|
AU653937B2
(en)
|
1991-04-17 |
1994-10-20 |
Medisup International N.V. |
Water-soluble polypeptides having high affinity for interferons alpha and beta
|
|
US5637481A
(en)
|
1993-02-01 |
1997-06-10 |
Bristol-Myers Squibb Company |
Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
|
|
IE922437A1
(en)
|
1991-07-25 |
1993-01-27 |
Idec Pharma Corp |
Recombinant antibodies for human therapy
|
|
WO1993015722A1
(en)
|
1992-02-07 |
1993-08-19 |
Syntex (Usa) Inc. |
Controlled delivery of pharmaceuticals from preformed porous microparticles
|
|
GB9300686D0
(en)
|
1993-01-15 |
1993-03-03 |
Imp Cancer Res Tech |
Compounds for targeting
|
|
US20030108548A1
(en)
|
1993-06-01 |
2003-06-12 |
Bluestone Jeffrey A. |
Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
|
|
GB9422383D0
(en)
|
1994-11-05 |
1995-01-04 |
Wellcome Found |
Antibodies
|
|
US6348343B2
(en)
|
1995-02-24 |
2002-02-19 |
Genentech, Inc. |
Human DNase I variants
|
|
US6121022A
(en)
|
1995-04-14 |
2000-09-19 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
US5739277A
(en)
|
1995-04-14 |
1998-04-14 |
Genentech Inc. |
Altered polypeptides with increased half-life
|
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
US6096871A
(en)
|
1995-04-14 |
2000-08-01 |
Genentech, Inc. |
Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
|
|
US6127977A
(en)
|
1996-11-08 |
2000-10-03 |
Cohen; Nathan |
Microstrip patch antenna with fractal structure
|
|
US5989830A
(en)
|
1995-10-16 |
1999-11-23 |
Unilever Patent Holdings Bv |
Bifunctional or bivalent antibody fragment analogue
|
|
US6482626B2
(en)
|
1996-02-05 |
2002-11-19 |
Genentech, Inc. |
Human DNase
|
|
US6716974B1
(en)
|
1996-05-31 |
2004-04-06 |
Maine Medical Center Research Institute |
Therapeutic and diagnostic methods and compositions based on jagged/notch proteins and nucleic acids
|
|
US6391607B1
(en)
|
1996-06-14 |
2002-05-21 |
Genentech, Inc. |
Human DNase I hyperactive variants
|
|
US7247302B1
(en)
|
1996-08-02 |
2007-07-24 |
Bristol-Myers Squibb Company |
Method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis
|
|
ATE386809T1
(de)
|
1996-08-02 |
2008-03-15 |
Bristol Myers Squibb Co |
Ein verfahren zur inhibierung immunglobulininduzierter toxizität aufgrund von der verwendung von immunoglobinen in therapie und in vivo diagnostik
|
|
US6653104B2
(en)
|
1996-10-17 |
2003-11-25 |
Immunomedics, Inc. |
Immunotoxins, comprising an internalizing antibody, directed against malignant and normal cells
|
|
WO1998016254A1
(en)
|
1996-10-17 |
1998-04-23 |
Immunomedics, Inc. |
Non-antigenic toxin-conjugate and fusion protein of internalizing receptor system
|
|
WO1998023289A1
(en)
|
1996-11-27 |
1998-06-04 |
The General Hospital Corporation |
MODULATION OF IgG BINDING TO FcRn
|
|
US6277375B1
(en)
|
1997-03-03 |
2001-08-21 |
Board Of Regents, The University Of Texas System |
Immunoglobulin-like domains with increased half-lives
|
|
US7074897B2
(en)
|
1997-06-16 |
2006-07-11 |
Genentech, Inc. |
Pro943 polypeptides
|
|
US20020192659A1
(en)
|
1997-09-17 |
2002-12-19 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
|
US6280991B1
(en)
|
1997-10-15 |
2001-08-28 |
Wisconsin Alumni Research Foundation |
Engineered cytotoxic ribonclease
|
|
US5840296A
(en)
|
1997-10-15 |
1998-11-24 |
Raines; Ronald T. |
Engineered cytotoxic ribonuclease A
|
|
US6528624B1
(en)
|
1998-04-02 |
2003-03-04 |
Genentech, Inc. |
Polypeptide variants
|
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
ES2292236T3
(es)
|
1998-04-02 |
2008-03-01 |
Genentech, Inc. |
Variantes de anticuerpos y sus fragmentos.
|
|
US6242195B1
(en)
|
1998-04-02 |
2001-06-05 |
Genentech, Inc. |
Methods for determining binding of an analyte to a receptor
|
|
GB9809951D0
(en)
|
1998-05-08 |
1998-07-08 |
Univ Cambridge Tech |
Binding molecules
|
|
EP1105427A2
(en)
|
1998-08-17 |
2001-06-13 |
Abgenix, Inc. |
Generation of modified molecules with increased serum half-lives
|
|
US6660843B1
(en)
|
1998-10-23 |
2003-12-09 |
Amgen Inc. |
Modified peptides as therapeutic agents
|
|
EP1006183A1
(en)
|
1998-12-03 |
2000-06-07 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Recombinant soluble Fc receptors
|
|
US6239257B1
(en)
|
1998-12-30 |
2001-05-29 |
Alfacell Corporation |
Family of proteins belonging to the pancreatic ribonuclease a superfamily
|
|
HU230769B1
(hu)
|
1999-01-15 |
2018-03-28 |
Genentech Inc. |
Módosított effektor-funkciójú polipeptid-változatok
|
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
IL147270A0
(en)
|
1999-07-02 |
2002-08-14 |
Genentech Inc |
Fusion peptides comprising a peptide ligand domain and a multimerization domain
|
|
US6175003B1
(en)
|
1999-09-10 |
2001-01-16 |
Alfacell Corporation |
Nucleic acids encoding ribonucleases and methods of making them
|
|
EP1246643A4
(en)
|
1999-10-14 |
2005-05-11 |
Jeffery A Ledbetter |
DNA VACCINES ENCODING ANTIGEN ASSOCIATED WITH CD40-BINDING DOMAIN
|
|
GB0029407D0
(en)
|
2000-12-01 |
2001-01-17 |
Affitech As |
Product
|
|
PT1355919E
(pt)
|
2000-12-12 |
2011-03-02 |
Medimmune Llc |
Moléculas com semivida longa, composições que as contêm e suas utilizações
|
|
US20030133939A1
(en)
|
2001-01-17 |
2003-07-17 |
Genecraft, Inc. |
Binding domain-immunoglobulin fusion proteins
|
|
US7829084B2
(en)
|
2001-01-17 |
2010-11-09 |
Trubion Pharmaceuticals, Inc. |
Binding constructs and methods for use thereof
|
|
US7754208B2
(en)
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
|
AU2002327164A1
(en)
|
2001-01-29 |
2002-12-09 |
Idec Pharmaceuticals Corporation |
Engineered tetravalent antibodies and methods of use
|
|
BR0206985A
(pt)
|
2001-01-29 |
2005-04-19 |
Idec Pharma Corp |
Anticorpos modificados e métodos de uso
|
|
AU2002248571B2
(en)
|
2001-03-07 |
2007-01-18 |
Merck Patent Gmbh |
Expression technology for proteins containing a hybrid isotype antibody moiety
|
|
JP4586310B2
(ja)
|
2001-07-04 |
2010-11-24 |
株式会社Ihi |
セラミックス複合部材の製造方法
|
|
US20060040262A1
(en)
|
2002-12-27 |
2006-02-23 |
Morris David W |
Novel compositions and methods in cancer
|
|
US20040002587A1
(en)
|
2002-02-20 |
2004-01-01 |
Watkins Jeffry D. |
Fc region variants
|
|
US7662925B2
(en)
|
2002-03-01 |
2010-02-16 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
|
US7317091B2
(en)
|
2002-03-01 |
2008-01-08 |
Xencor, Inc. |
Optimized Fc variants
|
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
|
CA2478011C
(en)
|
2002-03-01 |
2013-05-21 |
Immunomedics, Inc. |
Bispecific antibody point mutations for enhancing rate of clearance
|
|
CA2489446A1
(en)
|
2002-06-14 |
2003-12-24 |
Wisconsin Alumni Research Foundation |
Ribonuclease zymogen design
|
|
EP1534335B9
(en)
|
2002-08-14 |
2016-01-13 |
Macrogenics, Inc. |
Fcgammariib-specific antibodies and methods of use thereof
|
|
WO2004029207A2
(en)
|
2002-09-27 |
2004-04-08 |
Xencor Inc. |
Optimized fc variants and methods for their generation
|
|
US20060235208A1
(en)
|
2002-09-27 |
2006-10-19 |
Xencor, Inc. |
Fc variants with optimized properties
|
|
DE60334141D1
(de)
|
2002-10-15 |
2010-10-21 |
Facet Biotech Corp |
VERÄNDERUNG VON FcRn-BINDUNGSAFFINITÄTEN ODER VON SERUMHALBWERTSZEITEN VON ANTIKÖRPERN MITTELS MUTAGENESE
|
|
CA2503390A1
(en)
|
2002-11-01 |
2004-05-21 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
|
GB2395337B
(en)
|
2002-11-14 |
2005-12-28 |
Gary Michael Wilson |
Warning Unit
|
|
JP2006524039A
(ja)
|
2003-01-09 |
2006-10-26 |
マクロジェニクス，インコーポレーテッド |
変異型Ｆｃ領域を含む抗体の同定および作製ならびにその利用法
|
|
US8388955B2
(en)
|
2003-03-03 |
2013-03-05 |
Xencor, Inc. |
Fc variants
|
|
US20090010920A1
(en)
|
2003-03-03 |
2009-01-08 |
Xencor, Inc. |
Fc Variants Having Decreased Affinity for FcyRIIb
|
|
US7067298B2
(en)
|
2003-03-31 |
2006-06-27 |
Ambion, Inc. |
Compositions and methods of using a synthetic Dnase I
|
|
US7666417B2
(en)
*
|
2003-04-22 |
2010-02-23 |
Fred Hutchinson Cancer Research Center |
Methods and compositions for treating autoimmune diseases or conditions
|
|
US7754209B2
(en)
*
|
2003-07-26 |
2010-07-13 |
Trubion Pharmaceuticals |
Binding constructs and methods for use thereof
|
|
CN1871259A
(zh)
|
2003-08-22 |
2006-11-29 |
比奥根艾迪克Ma公司 |
具有改变的效应物功能的经改进的抗体和制备它的方法
|
|
GB0324368D0
(en)
|
2003-10-17 |
2003-11-19 |
Univ Cambridge Tech |
Polypeptides including modified constant regions
|
|
ES2672640T3
(es)
|
2003-11-05 |
2018-06-15 |
Roche Glycart Ag |
Moléculas de unión a antígeno con afinidad de unión a receptores Fc y función efectora incrementadas
|
|
WO2005063815A2
(en)
|
2003-11-12 |
2005-07-14 |
Biogen Idec Ma Inc. |
Fcϝ receptor-binding polypeptide variants and methods related thereto
|
|
WO2005047327A2
(en)
|
2003-11-12 |
2005-05-26 |
Biogen Idec Ma Inc. |
NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
|
|
US20050249723A1
(en)
|
2003-12-22 |
2005-11-10 |
Xencor, Inc. |
Fc polypeptides with novel Fc ligand binding sites
|
|
JP2008504008A
(ja)
|
2003-12-31 |
2008-02-14 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング |
改良された薬物動態を有するＦｃ−エリスロポエチン融合タンパク質
|
|
CA2552788C
(en)
|
2004-01-12 |
2013-09-24 |
Applied Molecular Evolution, Inc. |
Fc region variants
|
|
WO2005080586A1
(en)
|
2004-02-13 |
2005-09-01 |
Immunomedics, Inc. |
Fusion proteins containing recombinant cytotoxic rnases
|
|
EP1737890A2
(en)
|
2004-03-24 |
2007-01-03 |
Xencor, Inc. |
Immunoglobulin variants outside the fc region
|
|
WO2005123780A2
(en)
|
2004-04-09 |
2005-12-29 |
Protein Design Labs, Inc. |
Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
|
|
WO2005115477A2
(en)
|
2004-04-13 |
2005-12-08 |
Quintessence Biosciences, Inc. |
Non-natural ribonuclease conjugates as cytotoxic agents
|
|
WO2006085967A2
(en)
|
2004-07-09 |
2006-08-17 |
Xencor, Inc. |
OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS
|
|
CN103172731A
(zh)
|
2004-07-15 |
2013-06-26 |
赞科股份有限公司 |
优化的Fc变体
|
|
BRPI0514259A
(pt)
|
2004-08-11 |
2008-06-03 |
Trubion Pharmaceuticals Inc |
proteìna de fusão de domìnio de ligação
|
|
WO2006047350A2
(en)
|
2004-10-21 |
2006-05-04 |
Xencor, Inc. |
IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
|
|
DE102005000921A1
(de)
|
2005-01-07 |
2006-07-27 |
Siemens Ag |
Verfahren und Vorrichtung zur Broadband-Datenverteilung zwischen mehreren Benutzerendgeräten
|
|
DE102005009219A1
(de)
|
2005-02-25 |
2006-08-31 |
Martin-Luther-Universität Halle-Wittenberg |
Ribonuclease-Tandemenzyme und Verfahren zu ihrer Herstellung
|
|
WO2006105062A2
(en)
|
2005-03-29 |
2006-10-05 |
Verenium Corporation |
Altered antibody fc regions and uses thereof
|
|
JP2008539753A
(ja)
|
2005-05-09 |
2008-11-20 |
グリクアート バイオテクノロジー アクチェンゲゼルシャフト |
修飾ｆｃ領域およびｆｃ受容体との結合変更を有する抗原結合分子
|
|
US7655757B2
(en)
|
2005-06-16 |
2010-02-02 |
Wisconsin Alumni Research Foundation |
Cytotoxic ribonuclease variants
|
|
WO2006138458A1
(en)
|
2005-06-16 |
2006-12-28 |
Wisconsin Alumni Research Foundation |
Cytotoxic ribonuclease variants
|
|
US20080279850A1
(en)
|
2005-07-25 |
2008-11-13 |
Trubion Pharmaceuticals, Inc. |
B-Cell Reduction Using CD37-Specific and CD20-Specific Binding Molecules
|
|
HRP20140338T1
(hr)
|
2005-07-25 |
2014-06-20 |
Emergent Product Development Seattle, Llc |
Smanjenje broja b-stanica upotrebom molekula koje se specifiäśno vežu na cd37 i cd20
|
|
BRPI0617688A2
(pt)
|
2005-10-21 |
2011-06-07 |
Hoffmann La Roche |
método para expressão recombinante de um polipeptìdeo
|
|
BRPI0710011A2
(pt)
|
2006-04-14 |
2011-08-02 |
Trubion Pharmaceuticals Inc |
proteìnas de ligação compreendendo articulação de imunoglobulina e regiões fc dotadas de funções efetoras fc alteradas
|
|
ATE547123T1
(de)
|
2006-04-21 |
2012-03-15 |
Mab Factory Gmbh |
Antikörper-rnase-konjugat
|
|
GB0611444D0
(en)
|
2006-06-09 |
2006-07-19 |
Medical Res Council Technology |
Rnase H2 complex and genes therefor
|
|
WO2007146968A2
(en)
|
2006-06-12 |
2007-12-21 |
Trubion Pharmaceuticals, Inc. |
Single-chain multivalent binding proteins with effector function
|
|
EP1905841A1
(en)
|
2006-09-25 |
2008-04-02 |
Max Delbrück Centrum für Molekulare Medizin (MDC) Berlin-Buch; |
Trex1 as a marker for lupus erythematosus
|
|
EP2144930A1
(en)
|
2007-04-18 |
2010-01-20 |
ZymoGenetics, Inc. |
Single chain fc, methods of making and methods of treatment
|
|
US20090258005A1
(en)
|
2007-05-29 |
2009-10-15 |
Trubion Pharmaceuticals Inc. |
Therapeutic compositions and methods
|
|
WO2008156713A2
(en)
|
2007-06-12 |
2008-12-24 |
Wyeth |
Anti-cd20 therapeutic compositions and methods
|
|
JP2010532764A
(ja)
*
|
2007-07-06 |
2010-10-14 |
トゥルビオン・ファーマシューティカルズ・インコーポレーテッド |
Ｃ末端に配置された特異的結合性ドメインを有する結合性ペプチド
|
|
WO2009015345A1
(en)
|
2007-07-25 |
2009-01-29 |
Amgen Inc. |
Pharmaceutical compositions comprising fc fusion proteins
|
|
WO2009012600A1
(en)
|
2007-07-26 |
2009-01-29 |
Novagen Holding Corporation |
Fusion proteins
|
|
EP2220125A4
(en)
|
2007-11-13 |
2010-12-29 |
Sapphire Energy Inc |
PRODUCTION OF FC HYBRID POLYPEPTIDES IN EUKARYOTIC ALGAE
|
|
EP2365003A1
(en)
|
2008-04-11 |
2011-09-14 |
Emergent Product Development Seattle, LLC |
CD37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
|
|
BRPI0913778A2
(pt)
|
2008-09-26 |
2015-10-20 |
Genentech Inc |
"métodos de identificação de lúpus, para prever a responsividade, de diagnóstico, para auxiliar o diagnóstico, usos de um agente terapêutico, métodos de identificação, métodos, métodos para selecionar um paciente, para avaliar se um sujeito nestá em risco de desenvolver lúpus, de diagnóstico de lúpus, para prognóstico de lúpus e para auxiliar o prognóstico"
|
|
US8029782B2
(en)
|
2008-10-01 |
2011-10-04 |
Quintessence Biosciences, Inc. |
Therapeutic ribonucleases
|
|
KR101934923B1
(ko)
|
2009-11-02 |
2019-04-10 |
유니버시티 오브 워싱톤 스루 이츠 센터 포 커머셜리제이션 |
치료학적 뉴클레아제 조성물 및 방법
|
|
TWI529163B
(zh)
|
2011-01-25 |
2016-04-11 |
陶氏農業科學公司 |
用於製備４－胺基－５－氟－３－鹵素－６－（經取代之）吡啶甲酸酯的方法
|
|
KR20130129438A
(ko)
|
2011-02-23 |
2013-11-28 |
암젠 인크 |
Uvc 노출을 위한 세포 배양 배지 및 이와 관련된 방법
|
|
BR112013021785A8
(pt)
|
2011-02-25 |
2018-07-03 |
Recombinetics Inc |
animais geneticamente modificados e métodos para fazer os mesmos
|
|
PH12019502377A1
(en)
|
2011-04-21 |
2022-11-14 |
Isis Pharmaceuticals Inc |
Modulation of hepatitis b virus (hbv) expression
|
|
PH12013502441B1
(en)
|
2011-04-29 |
2019-02-08 |
Univ Washington |
Therapeutic nuclease compositions and methods
|
|
US20140178479A1
(en)
|
2011-08-12 |
2014-06-26 |
Perosphere, Inc. |
Concentrated Felbamate Formulations for Parenteral Administration
|
|
WO2013180295A1
(ja)
|
2012-06-01 |
2013-12-05 |
日本電信電話株式会社 |
パケット転送処理方法およびパケット転送処理装置
|
|
PL3063275T3
(pl)
|
2013-10-31 |
2020-03-31 |
Resolve Therapeutics, Llc |
Terapeutyczne fuzje nukleaza-albumina i sposoby
|
|
US9300829B2
(en)
|
2014-04-04 |
2016-03-29 |
Canon Kabushiki Kaisha |
Image reading apparatus and correction method thereof
|
|
JP7308034B2
(ja)
|
2016-07-01 |
2023-07-13 |
リゾルブ セラピューティクス， エルエルシー |
最適化二重ヌクレアーゼ融合物および方法
|
|
JP6866739B2
(ja)
*
|
2017-04-13 |
2021-04-28 |
住友ゴム工業株式会社 |
ゴムクローラ
|